Association of levels of c-reactive protein with positive and negative syndrome scale among patients with schizophrenia

Paper Details

Research Paper 21/02/2024
Views (74) Download (25)

Association of levels of c-reactive protein with positive and negative syndrome scale among patients with schizophrenia

Syed Muhammad Shahkar Ali, Moin Ahmed Ansari, Fawad Ahmed, Samina Qadir, Fazal Ur Rehman, Sher Ullah, Muhammed Ilyas, Muhammad Tahir Khan
Int. J. Biosci.24( 2), 175-181, February 2024.
Certificate: IJB 2024 [Generate Certificate]


The research was done to explore the “association of levels of CRP with Positive and Negative Syndrome Scale Score (PANSS) among patients of schizophrenia. This Cross-Sectional study comprised of a sample of 310 pre-diagnosed patients with Schizophrenia (diagnosed by psychiatrist as per the DSM V Criteria) of both gender with age range between 18 and 60 years with more than 6 months duration of illness. Patients were taken from Inpatient and Outpatient Department of Sir Cowasjee Jehangir Institute of Psychiatry, Hyderabad, chosen via non-probability consecutive sampling. An anonymous self-structured proforma which contained questions related to basic personal details, and particulars of disease (duration of illness and family history) and PANSS. Range of age in total patients in sample (n= 310) was 18-60 years with mean range of 32.88±8.29 years. The mean PANSS Score was found to be 57.08 ± 11.88. The General Psychopathology Scale Score was found to be 15.16 ± 5.62. The Positive Scale Score was 12.50 ± 3.65 while Negative Scale Score was found to be 29.42 ± 9.62. Raised CRP levels were significantly associated with Negative Symptoms Scale Score. The results of our research study suggest that there is a positive association of raised CRP levels with negative symptoms scales scores of schizophrenia. Future research studies are the need of the time to explore the relationship of inflammation in schizophrenia patients.


Akiyama K. 1999. Serum levels of soluble IL-2 receptor α, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration. Schizophrenia research 37(1), 97-106.

American Psychiatric Association DSMTF, American Psychiatric Association. 2013. Diagnostic and statistical manual of mental disorders: DSM-5 (Vol. 5, No. 5). Washington, DC: American psychiatric association. 

Andrade C. 2016. Anti-inflammatory strategies in the treatment of schizophrenia. Expert review of clinical pharmacology 9(2), 161-163.

Bachneff SA. 1996. Regional cerebral blood flow in schizophrenia and the local circuit neurons hypothesis. Schizophrenia bulletin 22(1), 163-182.

Courtet PH, Jaussent I, Genty C, Dupuy AM, Guillaume S, Ducasse D, Olié E. 2015. Increased CRP levels may be a trait marker of suicidal attempt. European neuropsychopharmacology 25(10), 1824-1831.

Dimitrov DH, Lee S, Yantis J, Honaker C, Braida N, Walss-Bass C. 2016. Elevated serum levels of high-sensitivity C-reactive proteins are associated with severe delusional symptoms in a subgroup of patients with schizophrenia. The Journal of Clinical Psychiatry 77(1), 6373.

Fernandes BS, Steiner J, Bernstein HG, Dodd S, Pasco JA, Dean OM, Berk M. 2016. C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications. Molecular psychiatry 21(4), 554-564.

Fond G, Godin O, Boyer L, Berna F, Andrianarisoa M, Coulon N, Leboyer M. 2019. Chronic low-grade peripheral inflammation is associated with ultra-resistant schizophrenia. Results from the FACE-SZ cohort. European archives of psychiatry and clinical neuroscience 269, 985-992.

Hanson DR, Gottesman II. 2005. Theories of schizophrenia: a genetic-inflammatory-vascular synthesis. BMC medical genetics 6(1), 1-17.

Husain MI, Chaudhry IB, Khoso AB, Husain MO, Hodsoll J, Ansari MA, Young AH. 2020. Minocycline and celecoxib as adjunctive treatments for bipolar depression: a multicentre, factorial design randomised controlled trial. The Lancet Psychiatry 7(6), 515-527.

Inoshita M, Numata S, Tajima A, Kinoshita M, Umehara H, Nakataki M, Ohmori T. 2016. A significant causal association between C-reactive protein levels and schizophrenia. Scientific reports 6(1), 26105.

Kim YK, Na KS, Myint AM, Leonard BE. 2016. The role of pro-inflammatory cytokines in neuroinflammation, neurogenesis and the neuroendocrine system in major depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry 64, 277-284.

Lahti AC, Holcomb HH, Medoff DR, Weiler M. A, Tamminga CA, Carpenter Jr WT. 2001. Abnormal patterns of regional cerebral blood flow in schizophrenia with primary negative symptoms during an effortful auditory recognition task. American Journal of Psychiatry 158(11), 1797-1808. DOI: 10.1176/appi.ajp.158.11.1797.

Lin A, Kenis G, Bignotti S, Tura GJB, De Jong R, Bosmans E, Maes M. 1998. The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophrenia research 32(1), 9-15.

Maes M, Chiavetto LB, Bignotti S, Tura GJB, Pioli R, Boin F, Altamura CA. 2000. Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics. European Neuropsychopharmacology 10(2), 119-124.

Maes M, Meltzer HY, Bosmans E, Bergmans R, Vandoolaeghe E, Ranjan R, Desnyder R. 1995. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. Journal of affective disorders 34(4), 301-309.

Metcalf SA, Jones PB, Nordstrom T, Timonen M, Mäki P, Miettunen J, Khandaker GM. 2017. Serum C-reactive protein in adolescence and risk of schizophrenia in adulthood: a prospective birth cohort study. Brain, behavior, and immunity, 59, 253-259.

Miller BJ, Culpepper N, Rapaport MH. 2014. C-reactive protein levels in schizophrenia: a review and meta-analysis. Clinical schizophrenia & related psychoses 7(4), 223–230.

Müller N, Riedel M, Gruber R, Ackenheil M, Schwarz MJ. 2000. The immune system and schizophrenia: an integrative view. Annals of the New York Academy of Sciences 917(1), 456-467.

Pollmächer T, Haack M, Schuld A, Kraus T, Hinze-Selch D. 2000. Effects of antipsychotic drugs on cytokine networks. Journal of psychiatric research 34(6), 369-382.

Rapaport MH, Lohr JB. 1994. Serum‐soluble interleukin‐2 receptors in neuroleptic‐naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia. Acta Psychiatrica Scandinavica 90(5), 311-315.

Santor DA, Ascher-Svanum H, Lindenmayer JP, Obenchain RL. 2007. Item response analysis of the Positive and Negative Syndrome Scale. Bmc Psychiatry 7, 1-10.

Shinba T, Nagano M, Kariya N, Ogawa K, Shinozaki T, Shimosato S, Hoshi Y. 200. Near-infrared spectroscopy analysis of frontal lobe dysfunction in schizophrenia. Biological psychiatry 55(2), 154-164. DOI: 10.1016/s0006-3223(03)00547-x.

Sirota P, Meiman M, Herschko R, Bessler H. 2005. Effect of neuroleptic administration on serum levels of soluble IL-2 receptor-alpha and IL-1 receptor antagonist in schizophrenic patients. Psychiatry research 134(2), 151-159.

Song Y, Ridker PM, Manson JE, Cook NR, Buring JE, Liu S. 2005. Magnesium intake, C-reactive protein, and the prevalence of metabolic syndrome in middle-aged and older US women. Diabetes care 28(6), 1438-1444.

Vaiva G, Cottencin O, Llorca PM, Devos P, Dupont S, Mazas O, Goudemand M. 2002. Regional cerebral blood flow in deficit/nondeficit types of schizophrenia according to SDS criteria. Progress in Neuro-Psychopharmacology and Biological Psychiatry 26(3), 481-485.